CF Valencia Life Sciences DST completed its exit on February 1, 2026 by way of a Section 721 roll, contributing to a REIT operating partnership in exchange for units. Cantor Fitzgerald lists the Delaware Statutory Trust (DST) as a completed program on its published track record.
Record | |
|---|---|
Trust | CF Valencia Life Sciences DST |
Sponsor | Cantor Fitzgerald |
First Form D | August 25, 2021 |
Exemption | 506(b) |
Offering amount | $40,400,000 |
Minimum investment | $250,000 |
Asset class as filed | Other Real Estate |
Exit type | Section 721 UPREIT roll (contribution to a REIT for operating-partnership units) |
Exit date | February 1, 2026 |
Hold, first Form D to exit | 4.4 years |
The Form D names no property, no tenant and no lease term. Those terms sat in the private placement memorandum, which is not a public document, so the address, the square footage and the acquisition price are outside the record Top1031 can cite.
No return figure accompanied the roll. There is no per-unit value for the operating-partnership units investors received, no stated valuation for the trust's real estate at the exchange, and no statement of how much of the offering ceiling was sold or how many investors held interests at the end.
The record establishes that the trust reached full cycle and how the exit was structured. It does not establish what the exchange was worth to the people who held interests in it.